Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023

Antunes, Liliana ✉; Mazagatos, Clara; Martínez-Baz, Iván; Gomez, Verónica; Borg, Maria-Louise; Petrović, Goranka; Duffy, Róisín; Dufrasne, François E; Dürrwald, Ralf; Lazar, Mihaela; Jancoriene, Ligita; Oroszi, Beatrix [Oroszi, Beatrix (népegészségügy, o...), author] Center of Epidemiology and Survaillance (SU / KSZE); Husa, Petr; Howard, Jennifer; Melo, Aryse; Pozo, Francisco; Pérez-Gimeno, Gloria; Castilla, Jesús; Machado, Ausenda; Džiugytė, Aušra; Karabuva, Svjetlana; Fitzgerald, Margaret; Fierens, Sébastien; Tolksdorf, Kristin; Popovici, Silvia-Odette; Mickienė, Auksė; Túri, Gergő [Túri, Gergő (népegészségügy), author] Center of Epidemiology and Survaillance (SU / KSZE); Součková, Lenka; Nicolay, Nathalie; Rose, Angela MC; European Hospital Vaccine Effectiveness Group2 [Collaborative Organization]

English Study Group (Journal Article) Scientific
Published: EUROSURVEILLANCE 1025-496X 1560-7917 29 (3) Paper: 2300708 , 8 p. 2024
  • SJR Scopus - Epidemiology: D1
Identifiers
Fundings:
  • Egészségbiztonság Nemzeti Laboratórium(RRF-2.3.1-21-2022-00006) Funder: NRDIO
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Cited in (6)
Citation styles: IEEEACMAPAChicagoHarvardCSLCopyPrint
2025-04-01 23:56